Zdrowie i gospodarka · 24/07/2026
Government Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML)
The National Cancer Institute (NCI) is seeking partners to co-develop or license NPM1 mutation-specific T cell receptors for treating acute myeloid leukemia (AML), a type of blood cancer.